Jupiter Neurosciences Expands CNS Pipeline with ALA-002 Licensing Deal Worth Up to $100M
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.
/ 2 items
The deal adds a differentiated psychedelic asset to Jupiter’s CNS pipeline.
Jupiter secured $100M rights to sell safer MDMA drug ALA-002 in the US, targeting mental health treatment growth.